Signia Pure C&G BCT IX vs Signia Pure Charge&Go MaX

The Signia Pure C&G BCT IX is a premium behind-the-ear prescription hearing aid released in 2025, earning an A grade with a SoundScore of 4.4/5 in our lab testing. Priced at $3,398, it ranks #16 among 39 prescription hearing aids tested. In our standardized testing, this device demonstrates particular strength in own-voice comfort, scoring 3.8/5—a solid result that sits 1.10 points above the category average. This makes it a noteworthy option for users who prioritize natural sound quality when speaking. Speech clarity also performs well, with speech-in-quiet at 3.8/5 (+0.39 points above average) and speech-in-noise at 2.5/5 (+0.43 points above average), though the latter remains mixed in absolute terms despite beating the category benchmark. Feedback handling presents an interesting picture: at 4.2/5, it's strong in absolute terms, though it falls 0.52 points below the category average of 4.72/5. Music streaming scores 2.7/5, essentially matching the category average. The device features rechargeable batteries, iPhone and Android streaming, and hands-free functionality. While the Pure C&G BCT IX delivers solid overall performance, shoppers in this premium price tier should note that competitors like the Phonak Sphere Infinio and Oticon Intent score higher in our testing. Budget-conscious buyers may also find comparable sound quality at lower price points from options like the Rexton Reach R-Li T80 at Costco. This hearing aid is best suited for users who value own-voice naturalness and reliable speech clarity in everyday listening situations.

The Signia Pure Charge&Go MaX is a behind-the-ear prescription hearing aid released in 2026 that earns an A grade with a SoundScore of 4.3/5 in HearAdvisor's lab testing. This strong overall performance reflects solid results across key listening scenarios, with particular strengths in own-voice comfort and speech understanding in noisy environments. In our testing, the Pure Charge&Go MaX demonstrated notable advantages over the prescription hearing aid category average. Own-voice comfort scored 1.00 points above the category average at 3.7/5, suggesting effective management of occlusion-related issues that many hearing aid users find bothersome. Speech in noise performance measured 0.65 points above average at 2.8/5—above the category average, but only mixed in absolute terms, indicating room for improvement in the most challenging listening situations. Speech in quiet scored a solid 3.6/5, landing 0.24 points above the category average. Music streaming measured 2.9/5, slightly above average but mixed in absolute terms. Feedback handling scored an excellent 4.6/5 in absolute terms, though this fell 0.12 points below the category average of 4.72/5, reflecting the generally strong feedback control across modern prescription devices. The device showed meaningful improvement from initial to tuned fitting, with the normalized score rising from 4.2/5 to 4.6/5 after professional adjustment. This suggests that working with a hearing care professional to optimize settings can unlock additional performance, particularly for speech understanding. The Pure Charge&Go MaX appears well-suited for users who prioritize natural own-voice quality and improved conversation clarity in moderately noisy settings.